Literature DB >> 28097866

Pharmacokinetics and Biodistribution of the Illegal Food Colorant Rhodamine B in Rats.

Yung-Yi Cheng1, Tung-Hu Tsai1,2,3,4.   

Abstract

The International Agency for Research on Cancer (IARC) demonstrated rhodamine B as a potential carcinogen in 1978. Nevertheless, rhodamine B has been illegally used as a colorant in food in many countries. Few pharmacokinetic and toxicological investigations have been performed since the first pharmacokinetic study on rhodamine B in 1961. The aims of this study were to develop a simple and sensitive high-performance liquid chromatography method with fluorescence detection for the quantitative detection of rhodamine B in the plasma and organs of rats and to estimate its pharmacokinetics and biodistribution. The results demonstrated that the oral bioavailabilities of rhodamine B were 28.3 and 9.8% for the low-dose and high-dose exposures, respectively. Furthermore, rhodamine B was highly accumulated in the liver and, to a lesser extent, the kidney, but was undetectable in the brain. These results provide useful information for improving the pharmacokinetics and biodistribution of rhodamine B, supporting additional food safety evaluations.

Entities:  

Keywords:  HPLC-FLD; biodistribution; oral bioavailability; pharmacokinetics; rhodamine B

Mesh:

Substances:

Year:  2017        PMID: 28097866     DOI: 10.1021/acs.jafc.6b04975

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  4 in total

1.  Perovskite-structured CaTiO3 coupled with g-C3N4 as a heterojunction photocatalyst for organic pollutant degradation.

Authors:  Ashish Kumar; Christian Schuerings; Suneel Kumar; Ajay Kumar; Venkata Krishnan
Journal:  Beilstein J Nanotechnol       Date:  2018-02-21       Impact factor: 3.649

2.  Rhodamine B oxidation promoted by P450-bioinspired Jacobsen catalysts/cellulose systems.

Authors:  Lucas Bomfim Bolzon; Anna Karolina Dos Santos Bindeiro; Ana Luiza Marques de Oliveira Souza; Lucas Dimarô Zanatta; Rodrigo de Paula; Bruna Costa Cerqueira; Joicy Santamalvina Dos Santos
Journal:  RSC Adv       Date:  2021-11-02       Impact factor: 3.361

Review 3.  Targeted nanoscale therapeutics for myocardial infarction.

Authors:  Holly L Sullivan; Nathan C Gianneschi; Karen L Christman
Journal:  Biomater Sci       Date:  2020-12-23       Impact factor: 6.843

4.  Multiple Sclerosis: LIFNano-CD4 for Trojan Horse Delivery of the Neuro-Protective Biologic "LIF" Into the Brain: Preclinical Proof of Concept.

Authors:  Raul de la Flor; Janette Robertson; Rostislav V Shevchenko; Mo Alavijeh; Sean Bickerton; Tarek Fahmy; Su M Metcalfe
Journal:  Front Med Technol       Date:  2021-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.